{"product_id":"new-product-642955","title":"Monoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)","description":"\u003cp\u003eWestern blotting: 0.5-2µg\/mL;1:500-2000\u003cbr\u003e;Immunohistochemistry: 5-20µg\/mL;1:50-200\u003cbr\u003e;Immunocytochemistry: 5-20µg\/mL;1:50-200\u003cbr\u003e;Optimal working dilutions must be determined by end user.\u003c\/p\u003e\n\u003cp\u003eProduct No.\u003c\/p\u003e\n\u003cp\u003eMAA788Ra21\u003c\/p\u003e\n\u003cp\u003eOrganism Species\u003c\/p\u003e\n\u003cp\u003eRattus norvegicus (Rat).\u003c\/p\u003e\n\u003cp\u003eSource\u003c\/p\u003e\n\u003cp\u003eMonoclonal antibody preparation\u003c\/p\u003e\n\u003cp\u003eHost\u003c\/p\u003e\n\u003cp\u003eMouse\u003c\/p\u003e\n\u003cp\u003ePotency (Clone Number)\u003c\/p\u003e\n\u003cp\u003eD6\u003c\/p\u003e\n\u003cp\u003eIg Isotype\u003c\/p\u003e\n\u003cp\u003eIgG2a Kappa\u003c\/p\u003e\n\u003cp\u003ePurification\u003c\/p\u003e\n\u003cp\u003eProtein A + Protein G affinity chromatography\u003c\/p\u003e\n\u003cp\u003eLabel\u003c\/p\u003e\n\u003cp\u003eNone\u003c\/p\u003e\n\u003cp\u003eImmunogen\u003c\/p\u003e\n\u003cp\u003eRPA788Ra01-Recombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/p\u003e\n\u003cp\u003eBuffer Formulation\u003c\/p\u003e\n\u003cp\u003e0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.\u003c\/p\u003e\n\u003cp\u003eTraits\u003c\/p\u003e\n\u003cp\u003eLiquid\u003c\/p\u003e\n\u003cp\u003eConcentration\u003c\/p\u003e\n\u003cp\u003e1mg\/ml\u003c\/p\u003e\n\u003cp\u003eOrganism Species More\u003c\/p\u003e\n\u003cp\u003en\/a\u003c\/p\u003e\n\u003cp\u003eApplications\u003c\/p\u003e\n\u003cp\u003eWB; IHC; ICC; IP.\u003c\/p\u003e\n\u003cp\u003eIf the antibody is used in flow cytometry, please check FCM antibodies.\u003c\/p\u003e\n\u003cp\u003eUOM\u003c\/p\u003e\n\u003cp\u003e20µl 100µl 200µl 1ml 10ml\u003c\/p\u003e\n\u003ch3\u003eSPECIFITY\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe antibody is a mouse monoclonal antibody raised against PDL1. It has been selected for its ability to recognize PDL1 in immunohistochemical staining and western blotting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eUSAGE\u003c\/h3\u003e\n\u003cdiv class=\"img_parent\"\u003e\n\u003cp\u003eWestern blotting: 0.5-2µg\/mL;1:500-2000\u003cbr\u003eImmunohistochemistry: 5-20µg\/mL;1:50-200\u003cbr\u003eImmunocytochemistry: 5-20µg\/mL;1:50-200\u003cbr\u003eOptimal working dilutions must be determined by end user.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eSTORAGE\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eStore at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eSTABILITY\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.\u003c\/p\u003e\n\u003cdiv class=\"product_reference\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eMagazine\u003c\/td\u003e\n\u003ctd\u003eCitations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChinese Journal of Cancer\u003c\/td\u003e\n\u003ctd\u003eLevel of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3937742\/\" target=\"_blank\"\u003eNCBI: PMC3937742\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeukemia.?\u003c\/td\u003e\n\u003ctd\u003eHigh level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24732592\" target=\"_blank\"\u003ePubmed:24732592\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes?Metab Res Rev.\u003c\/td\u003e\n\u003ctd\u003ePD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24816853\" target=\"_blank\"\u003ePubmed:24816853\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLancet Haematol\u003c\/td\u003e\n\u003ctd\u003eRatios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26686046\" target=\"_blank\"\u003ePubMed: 26686046\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEur J Cancer. \u003c\/td\u003e\n\u003ctd\u003eHigh levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27039170\" target=\"_blank\"\u003ePubmed:27039170\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Cancer Research and Clinical Oncology\u003c\/td\u003e\n\u003ctd\u003eSerum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2184-6\" target=\"_blank\"\u003earticle:10.1007\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Hematology \u0026amp; Oncology\u003c\/td\u003e\n\u003ctd\u003ePD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27737703\" target=\"_blank\"\u003epubmed:27737703\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLung Cancer.\u003c\/td\u003e\n\u003ctd\u003eHigh plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28212990\" target=\"_blank\"\u003epubmed:28212990\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncotarget\u003c\/td\u003e\n\u003ctd\u003eSoluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27780932\" target=\"_blank\"\u003epubmed:27780932\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncotarget\u003c\/td\u003e\n\u003ctd\u003eHigh post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK\/T cell lymphoma patients.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27105512\" target=\"_blank\"\u003epubmed:27105512\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncotarget. \u003c\/td\u003e\n\u003ctd\u003eSoluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27566569\" target=\"_blank\"\u003epubmed:27566569\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer Immunol Immunother.\u003c\/td\u003e\n\u003ctd\u003eProgrammed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28349165\" target=\"_blank\"\u003epubmed:28349165\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeukemia\u003c\/td\u003e\n\u003ctd\u003eSoluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.nature.com\/leu\/journal\/v31\/n4\/full\/leu2016385a.html\" target=\"_blank\"\u003eleu2016385a\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicine\u003c\/td\u003e\n\u003ctd\u003ePlasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28207525\" target=\"_blank\"\u003epubmed:28207525\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllergology International \u003c\/td\u003e\n\u003ctd\u003eInverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27617656\" target=\"_blank\"\u003epubmed:27617656\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicine\u003c\/td\u003e\n\u003ctd\u003ePlasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5319514\/\" target=\"_blank\"\u003ePMC5319514\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmerican Journal of Respiratory and Critical Care Medicine\u003c\/td\u003e\n\u003ctd\u003eSoluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM)\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.atsjournals.org\/doi\/pdf\/10.1164\/ajrccm-conference.2018.197.1_MeetingAbstracts.A4693\" target=\"_blank\"\u003ePdf:10.1164\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Lung Cancer\u003c\/td\u003e\n\u003ctd\u003eSoluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29859759\" target=\"_blank\"\u003ePubmed:29859759\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Rheumatology\u003c\/td\u003e\n\u003ctd\u003eIncreased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29419471\" target=\"_blank\"\u003ePubmed:29419471\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTranslational Oncology\u003c\/td\u003e\n\u003ctd\u003eHigh Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29698935\" target=\"_blank\"\u003ePubmed:29698935\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunology Letters\u003c\/td\u003e\n\u003ctd\u003eIncreased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0165247818302463\" target=\"_blank\"\u003ePubmed: 30236481\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Cancer Research and Clinical Oncology\u003c\/td\u003e\n\u003ctd\u003ePre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/link.springer.com\/article\/10.1007\/s00432-018-2758-6\" target=\"_blank\"\u003ePubmed: 30267213\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnals of Surgical Oncology\u003c\/td\u003e\n\u003ctd\u003eSoluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between …\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/link.springer.com\/article\/10.1245\/s10434-018-07112-x\" target=\"_blank\"\u003ePubmed: 30565045\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmerican Journal of Reproductive Immunology\u003c\/td\u003e\n\u003ctd\u003eIdentification of programmed cell death 1 and its ligand in the testicular tissue of mice\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/aji.13079\" target=\"_blank\"\u003ePubmed: 30578744\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePLoS One\u003c\/td\u003e\n\u003ctd\u003eClinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated …\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0212978\" target=\"_blank\"\u003ePubmed: 30807610\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndocrine Connections\u003c\/td\u003e\n\u003ctd\u003eElevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/aop\/ec-19-0210.xml\" target=\"_blank\"\u003ePubmed: 31252406\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScientific Reports\u003c\/td\u003e\n\u003ctd\u003ePrognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6668419\/\" target=\"_blank\"\u003ePubmed: 31366979\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCritical Reviews in Oncology \/ Hematology\u003c\/td\u003e\n\u003ctd\u003eThe Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31675543\/\" target=\"_blank\"\u003ePubmed: 31675543\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePLoS One\u003c\/td\u003e\n\u003ctd\u003eClinical implications of APOBEC3A and 3B expression in patients with breast cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32176735\/\" target=\"_blank\"\u003ePubmed: 32176735\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancers\u003c\/td\u003e\n\u003ctd\u003ePredictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32085544\/\" target=\"_blank\"\u003ePubmed: 32085544\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eSerum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32054467\/\" target=\"_blank\"\u003ePubmed: 32054467\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLIVER INTERNATIONAL\u003c\/td\u003e\n\u003ctd\u003eThe prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32780918\/\" target=\"_blank\"\u003ePubmed: 32780918\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCANCER IMMUNOLOGY IMMUNOTHERAPY\u003c\/td\u003e\n\u003ctd\u003ePrognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32577816\/\" target=\"_blank\"\u003ePubmed: 32577816\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eSoluble PD-L1: a potential immune marker for HIV-1 infection and virological failure\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32443313\/\" target=\"_blank\"\u003ePubmed: 32443313\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer Immunol Immunother\u003c\/td\u003e\n\u003ctd\u003eThe clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33688997\" target=\"_blank\"\u003e33688997\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActa Biochim Biophys Sin\u003c\/td\u003e\n\u003ctd\u003ePrognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34180502\/\" target=\"_blank\"\u003e34180502\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMBO J\u003c\/td\u003e\n\u003ctd\u003eMicroglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34825707\/\" target=\"_blank\"\u003e34825707\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMol Pharm\u003c\/td\u003e\n\u003ctd\u003eA Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34910492\/\" target=\"_blank\"\u003e34910492\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMol Hum Reprod\u003c\/td\u003e\n\u003ctd\u003eMacrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35404426\/\" target=\"_blank\"\u003ePubmed:35404426\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Nanobiotechnology\u003c\/td\u003e\n\u003ctd\u003eMicrobial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35705974\/\" target=\"_blank\"\u003ePubmed:35705974\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicina\u003c\/td\u003e\n\u003ctd\u003eAssessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A …\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35208526\/\" target=\"_blank\"\u003ePubmed:35208526\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product_relation\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eCatalog No.\u003c\/td\u003e\n\u003ctd class=\"td_2\"\u003eRelated products for research use of Rattus norvegicus (Rat) Organism species\u003c\/td\u003e\n\u003ctd class=\"td_3\"\u003eApplications (RESEARCH USE ONLY!)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPA788Ra01\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/RPA788Ra01.html\"\u003eRecombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003ePositive Control; Immunogen; SDS-PAGE; WB.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePAA788Ra01\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/PAA788Ra01.html\"\u003ePolyclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA788Ra24\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA788Ra24.html\"\u003eMonoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA788Ra22\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA788Ra22.html\"\u003eMonoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA788Ra23\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA788Ra23.html\"\u003eMonoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA788Ra21\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA788Ra21.html\"\u003eMonoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEA788Ra\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/SEA788Ra.html\"\u003eELISA Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eEnzyme-linked immunosorbent assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLMA788Ra\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/LMA788Ra.html\"\u003eMagnetic Luminex Assay Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc.\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eMagnetic Luminex Assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Cloud-clone","offers":[{"title":"200µl \/ 1mg\/ml \/ Rattus norvegicus (Rat)","offer_id":47594139418904,"sku":"MAA788Ra21","price":376.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/products\/Logo_Cloud_Clone_c60b8989-2d12-4c14-b876-55aa0fcf0b89.png?v=1706288860","url":"https:\/\/danabiosci.com\/products\/new-product-642955","provider":"Dana Bioscience","version":"1.0","type":"link"}